KAIVEXIN® - 20/40/60/80
Route of administration
Subcutaneous / Intravascular
Composition - Each Pre-filled Syringe Contains:
Enoxaparin Sodium I.P..….20 mg
(Porcine Derived)
Equivalent to 2000 IU of Anti-factor Xa Activity
Water For Injections I.P…….....q.s. to 0.2 mL
Composition - Each Pre-filled Syringe Contains:
Enoxaparin Sodium I.P..….40 mg
(Porcine Derived)
Equivalent to 4000 IU of Anti-factor Xa Activity
Water For Injections I.P…….....q.s. to 0.4 mL
Composition - Each Pre-filled Syringe Contains:
Enoxaparin Sodium I.P..….60 mg
(Porcine Derived)
Equivalent to 6000 IU of Anti-factor Xa Activity
Water For Injections I.P…….....q.s. to 0.6 mL
Composition - Each Pre-filled Syringe Contains:
Enoxaparin Sodium I.P..….80 mg
(Porcine Derived)
Equivalent to 8000 IU Anti-factor Xa Activity
Water For Injections I.P……….q.s. to 0.8 mL
The prophylaxis of thromboembolic disorders of venous origin, in particular those which may be associated with orthopaedic or general surgery.
The prophylaxis of venous thromboembolism in medical patients bedridden due to acute illnesses including cardiac insufficiency, respiratory failure, or severe infections.
The treatment of venous thromboembolic disease presenting with deep vein thrombosis, pulmonary embolism or both.
The treatment of unstable angina and non-Q-wave myocardial infarction administered concurrently with aspirin.
Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) including patients to be managed medically or with subsequent
Percutaneous Coronary Intervention (PCI). The prevention of thrombus formation in the extracorporeal circulation during haemodialysis